The taxanes: toxicity and quality of life considerations in advanced ovarian cancer

gan Guastalla III, J P, Diéras, V
Cyhoeddwyd 2003

Expert perspectives on biosimilar monoclonal antibodies in breast cancer

gan Cortés, J., Curigliano, G., Diéras, V.
Cyhoeddwyd 2014

Tumour growth kinetics assessment: added value to RECIST in cancer patients treated with molecularly targeted agents

gan Le Tourneau, C, Servois, V, Diéras, V, Ollivier, L, Tresca, P, Paoletti, X
Cyhoeddwyd 2012

Phase II multicentre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer

gan Bonneterre, J, Dieras, V, Tubiana-Hulin, M, Bougnoux, P, Bonneterre, M-E, Delozier, T, Mayer, F, Culine, S, Dohoulou, N, Bendahmane, B
Cyhoeddwyd 2004

P08.03 2B3-101, GLUTATHIONE PEGYLATED LIPOSOMAL DOXORUBICIN, IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMAS AND BREAST CANCER BRAIN METASTASES

gan Brandsma, D., Dieras, V., Altintas, S., Anders, C., Arnedos, M., Gelderblom, H., Soetekouw, P., Jager, A., van Linde, M., Aftimos, P.
Cyhoeddwyd 2014

Low immunogenicity of seasonal trivalent influenza vaccine among patients receiving docetaxel for a solid tumour: results of a prospective pilot study

gan Loulergue, P, Alexandre, J, Iurisci, I, Grabar, S, Medioni, J, Ropert, S, Dieras, V, Le Chevalier, F, Oudard, S, Goldwasser, F, Lebon, P, Launay, O
Cyhoeddwyd 2011

Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exp...

gan Krop, I. E., Lin, N. U., Blackwell, K., Guardino, E., Huober, J., Lu, M., Miles, D., Samant, M., Welslau, M., Diéras, V.
Cyhoeddwyd yn Ann Oncol (2015)

A multicentre phase II study of docetaxel 75 mg m-2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. Europe...

gan Dieras, V., Chevallier, B., Kerbrat, P., Krakowski, I., Roche, H., Misset, J. L., Lentz, M. A., Azli, N., Murawsky, M., Riva, A., Pouillart, P., Fumoleau, P.
Cyhoeddwyd 1996

Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer

gan Pierga, J-Y, Mouret, E, Diéras, V, Laurence, V, Beuzeboc, P, Dorval, T, Palangié, T, Jouve, M, Vincent-Salomon, A, Scholl, S, Extra, J-M, Asselain, B, Pouillart, P
Cyhoeddwyd 2000

A phase I pharmacokinetic study of the vascular disrupting agent ombrabulin (AVE8062) and docetaxel in advanced solid tumours

gan Eskens, F A L M, Tresca, P, Tosi, D, Van Doorn, L, Fontaine, H, Van der Gaast, A, Veyrat-Follet, C, Oprea, C, Hospitel, M, Dieras, V
Cyhoeddwyd 2014

Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapi...

gan Macaulay, V. M., Middleton, M. R., Protheroe, A. S., Tolcher, A., Dieras, V., Sessa, C., Bahleda, R., Blay, J.-Y., LoRusso, P., Mery-Mignard, D., Soria, J.-C.
Cyhoeddwyd 2013

HER2 status of bone marrow micrometastasis and their corresponding primary tumours in a pilot study of 27 cases: a possible tool for anti-HER2 therapy management?

gan Vincent-Salomon, A, Pierga, J-Y, Couturier, J, d'Enghien, C D, Nos, C, Sigal-Zafrani, B, Lae, M, Fréneaux, P, Diéras, V, Thiéry, J-P, Sastre-Garau, X
Cyhoeddwyd 2007

A dose-escalation study of indisulam in combination with capecitabine (Xeloda) in patients with solid tumours

gan Siegel-Lakhai, W S, Zandvliet, A S, Huitema, A D R, Tibben, M M, Milano, G, Girre, V, Diéras, V, King, A, Richmond, E, Wanders, J, Beijnen, J H, Schellens, J H M
Cyhoeddwyd 2008

Phase I study of lapatinib plus vinorelbine in patients with locally advanced or metastatic breast cancer overexpressing HER2

gan Brain, E, Isambert, N, Dalenc, F, Diéras, V, Bonneterre, J, Rezai, K, Jimenez, M, Mefti-Lacheraf, F, Cottura, E, Tresca, P, Vanlemmens, L, Mahier-Aït Oukhatar, C, Lokiec, F, Fumoleau, P
Cyhoeddwyd 2012

A phase I clinical and pharmacokinetic study of capecitabine (Xeloda®) and irinotecan combination therapy (XELIRI) in patients with metastatic gastrointestinal tumours

gan Delord, J P, Pierga, J Y, Dieras, V, Bertheault-Cvitkovic, F, Turpin, F L, Lokiec, F, Lochon, I, Chatelut, E, Canal, P, Guimbaud, R, Mery-Mignard, D, Cornen, X, Mouri, Z, Bugat, R
Cyhoeddwyd 2005

Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial

gan Rugo, H S, Diéras, V, Gelmon, K A, Finn, R S, Slamon, D J, Martin, M, Neven, P, Shparyk, Y, Mori, A, Lu, D R, Bhattacharyya, H, Bartlett, C Huang, Iyer, S, Johnston, S, Ettl, J, Harbeck, N
Cyhoeddwyd yn Ann Oncol (2018)

LBA16 IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or meta...

gan Emens, L.A., Adams, S., Barrios, C.H., Dieras, V.C., Iwata, H., Loi, S., Rugo, H.S., Schneeweiss, A., Winer, E.P., Patel, S., Henschel, V., Swat, A., Kaul, M., Molinero, L., Chui, S.Y., Schmid, P.
Cyhoeddwyd yn Ann Oncol (2020)

Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up

gan Rugo, H. S., Finn, R. S., Diéras, V., Ettl, J., Lipatov, O., Joy, A. A., Harbeck, N., Castrellon, A., Iyer, S., Lu, D. R., Mori, A., Gauthier, E. R., Bartlett, C. Huang, Gelmon, K. A., Slamon, D. J.
Cyhoeddwyd yn Breast Cancer Res Treat (2019)

Safety and immunogenicity of neoadjuvant treatment using WT1-immunotherapeutic in combination with standard therapy in patients with WT1-positive Stage II/III breast cancer: a rand...

gan Higgins, M., Curigliano, G., Dieras, V., Kuemmel, S., Kunz, G., Fasching, P. A., Campone, M., Bachelot, T., Krivorotko, P., Chan, S., Ferro, A., Schwartzberg, L., Gillet, M., De Sousa Alves, P. M., Wascotte, V., Lehmann, F. F., Goss, P.
Cyhoeddwyd yn Breast Cancer Res Treat (2017)

Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases

gan Turner, N C, Finn, R S, Martin, M, Im, S -A, DeMichele, A, Ettl, J, Diéras, V, Moulder, S, Lipatov, O, Colleoni, M, Cristofanilli, M, Lu, D R, Mori, A, Giorgetti, C, Iyer, S, Bartlett, C Huang, Gelmon, K A
Cyhoeddwyd yn Ann Oncol (2018)